As the 2020 pandemic became a distant memory and millions of Americans returned back to their old lives, some were left ...

Ferring Pharmaceuticals presented the initial results from an ongoing Phase 3 trial (NCT05704244) in Japan assessing the efficacy and safety of ADSTILADRIN® (nadofaragene firadenovec-vncg) in patients ...

First results from a Phase 3 trial conducted across 25 centers in Japan were presented at the Annual Meeting of the Japanese Urological Association ...

Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD's Innovative Dual-Targeting CAR-T Therapy, "P134 Cell Injection," which has received Investigational New Drug (IND) ...

Ferring Pharma’s Adstiladrin is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy. Its safety and efficacy was evaluated in a multi-centre clinical study of ...

As development began on a potential COVID-19 vaccine, the foundation had already been established – with a chimpanzee adenovirus vector having been previously tested against MERS, where it had ...

Age ranged between 23 and 81 (average 51). Vaccination was the only possible trigger in all cases. Six patients had received adenoviral vector-based vaccines (four received AstraZeneca and two ...

Treatment with fidanacogene elaparvovec, a recombinant adeno-associated virus (AAV) vector developed for the treatment of hemophilia B, led to sustained expression of the high-activity factor IX ...

Southern RNA is an Australian CDMO specialising in producing nucleic acid products that support the clinical development of ...